Zacks Investment Research covered ProNAi Therapeutics Inc (NASDAQ:DNAI), stepping up its target to $2.00 earlier today
- Updated: October 16, 2016
Zacks Investment Research raised the target price of ProNAi Therapeutics Inc (NASDAQ:DNAI) to $2.00 stating a potential upside of 0.10%.
Yesterday ProNAi Therapeutics Inc (NASDAQ:DNAI) traded -3.23% lower at $1.81. The company’s 50-day moving average is $1.85 and its 200-day moving average is $3.31. The last closing price is down -45.66% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 445,557 shares of the stock traded hands, down from an average trading volume of 758,483
See Chart Below
ProNAi Therapeutics Inc has a 52 week low of $1.77 and a 52 week high of $20.85 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 4 brokers have issued a research note on the company. The average stock price target is $29.50 with 3 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About ProNAi Therapeutics Inc (NASDAQ:DNAI)
ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer. The Company's PNT2258 is a formulation of its single-stranded 24-base DNAi oligonucleotide, known as PNT100, encapsulated in the SMARTICLES Lipid Nanoparticle (LNP). The Company's PNT2258 consists of over two components, including PNT100 DNAi Oligonucleotide and LNP Delivery Technology. It has conducted over two clinical trials for PNT2258, which include a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.